Reply to "New IFSO/ASMBS Indications for Metabolic and Bariatric Surgery? Yes, After Failure of Best Nonsurgical Therapy"

Affiliations

¹ Department of Surgery, Stanford School of Medicine and VA Palo Alto Health Care System, 3801 Miranda Avenue, GS 112, Palo Alto, CA, 94304, USA. daneisenberg@stanford.edu.
² Department of Surgery, Center for Metabolic and Bariatric Surgery, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
³ Prisma Health, Department of Surgery, University of South Carolina School of Medicine, Greenville, SC, USA.

Comment

Dan Eisenberg et al. Obes Surg. 2023 Aug.

. 2023 Aug;33(8):2594-2595.

doi: 10.1007/s11695-023-06667-3. Epub 2023 Jun 13.

¹ Department of Surgery, Stanford School of Medicine and VA Palo Alto Health Care System, 3801 Miranda Avenue, GS 112, Palo Alto, CA, 94304, USA. daneisenberg@stanford.edu.
² Department of Surgery, Center for Metabolic and Bariatric Surgery, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
³ Prisma Health, Department of Surgery, University of South Carolina School of Medicine, Greenville, SC, USA.

No abstract available

Comment on

2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery.
Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, de Luca M, Faria SL, Goodpaster KPS, Haddad A, Himpens JM, Kow L, Kurian M, Loi K, Mahawar K, Nimeri A, O'Kane M, Papasavas PK, Ponce J, Pratt JSA, Rogers AM, Steele KE, Suter M, Kothari SN. Eisenberg D, et al. Obes Surg. 2023 Jan;33(1):3-14. doi: 10.1007/s11695-022-06332-1. Obes Surg. 2023. PMID: 36336720 Free PMC article.
New IFSO/ASMBS Indications for Metabolic and Bariatric Surgery? Yes, After Failure of Best Nonsurgical Therapy.
Valdes S, Vilarrasa N, Rubio-Herrera MA, de Hollanda A; Area of Obesity of the Spanish Society of Endocrinology and Nutrition (Obesity SEEN). Valdes S, et al. Obes Surg. 2023 Aug;33(8):2592-2593. doi: 10.1007/s11695-023-06665-5. Epub 2023 Jun 20. Obes Surg. 2023. PMID: 37338796 No abstract available.

1. Gastrointestinal surgery for severe obesity. NIH Consens Dev Conf Consens Statement 1991;9(1):1–20.
1. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Obes Surg. 2023;33:3–14. - DOI - PubMed
1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. - DOI - PubMed
1. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083–91. - DOI - PubMed - PMC
1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–16. - DOI - PubMed